Eos Advisory — Full Portfolio
22 tracked investments · listed companies and verified rows first
Bioliberty develops the Lifehub Clinic system, combining soft robotic wearables, gamified therapy, and AI insights to help clinicians deliver physical and occupational therapy to more patients.
Digital HealthMedical DevicesRobotics
Biotangents develops AmpliSpec, a LAMP-based molecular diagnostics platform for veterinary use that delivers pathogen-specific results in under two hours at the point of care, in laboratories, or embedded within partner systems.
AgTechBiotechMedical Devices
Carcinotech produces 3D-bioprinted tumour models using established cancer cell lines and patient-derived tissue, offering assay-ready models and preclinical oncology services for drug testing and translational research.
BiotechDeep TechHealthtechScotland
Albert Nicholl(Director)Ishani Malhotra(Executive Officer, Director)Ian David Waddell(Director)
Concinnity Genetics develops control mechanisms to improve the safety of cell and gene therapies, using an AI platform and synthetic biology to help biopharmaceutical partners design and optimise their gene therapies.
AI & Machine LearningBiotechHealthtechEdinburgh, GB
Jessica Birt(Co-founder & CEO)Matthew Dale(Co-founder & CSO)
Cumulus Oncology builds a risk-adjusted portfolio of preclinical-stage oncology drug assets, using a platform-agnostic, data- and milestone-driven curation process to advance cancer therapeutics for defined patient populations with high unmet medical need.
BiotechHealthtech
Clare Wareing(CEO)
Dxcover develops a multi-omic liquid biopsy platform that combines infrared light spectroscopy and machine learning to detect multiple cancers at an early stage.
AI & Machine LearningBiotechMedical Devices
ENOUGH produces sustainable food ingredients and works with customers, suppliers, and partners toward its mission.
FoodTechImpact & Social Good
EnsiliTech develops ensilication technology, a silica-based method to stabilise vaccines and biopharmaceuticals so they can be stored and transported without refrigeration.
BiotechCleantechDeep TechHealthtechMedical Devices
Asel Sartbaeva(Co-Founder & CEO)Matt Slade(Co-Founder & Chief of Staff)Stephen Wells(Co-Founder & Advisor)Aswin Doekhie(Co-Founder & CTO)Sabine Ficek(CFO)Simon Bennett(Chief Commercial Officer)
ILC Therapeutics is a biotechnology company developing hybrid interferon therapeutics, including its Alfacyte product, based on an interferon platform.
BiotechDeep TechHealthtechMedical Devices
Owain Millington(CEO)
Nami Surgical is a company developing surgical technology and seeks investors and partners across clinical, commercial, and technological domains.
HealthtechMedical DevicesRoboticsGlasgow, GB
Nico Fenu(Co-Founder & Chief Operating Officer)REBECCA CLEARY(Executive Officer, Director)NICOLA GIUSEPPE FENU(Executive Officer, Director)NIKKI PAMELA PALFREY(Director)ALBERT NICHOLL(Director)Rebecca Cleary(Co-Founder & Chief Technical Officer)
Naturbeads develops biodegradable cellulose microspheres to replace microplastics in consumer products such as cosmetics and paints.
Circular EconomyCleantechNew MaterialsItaly, IT
Marco Meuli(Operator)Janet Scott(Co-founder)Davide Mattia(Co-founder)Giovanna Laudisio(Co-founder)
Developed technology embedding pure silver particles into fibres as an ecologically sound, non-toxic antimicrobial coating for paints and textiles.
SILVERbac is a patented antimicrobial textile technology that permanently incorporates pure silver particles into fibres, making the treatment non-leaching, non-toxic, and eco-friendly.
Advanced ManufacturingCleantechHealthtechNew MaterialsDubai, GB
Wobble Genomics operates an RNA sequencing platform that captures full-length RNA transcripts to identify long RNA biomarkers and novel isoforms for precision medicine.
BiotechDeep TechDigital HealthHealthtechMedical DevicesEdinburgh
Joanna Smart(Director)Richard Izen Kuo(Executive Officer, Director)Lee James Lindley(Director)John Harris Leamon(Director)Trevor John Nicholls(Director)John Robert Fraser Duncan(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.